Publication:
A Delphi consensus on the management of oral anticoagulation in patients with non-valvular atrial fibrillation in Spain: ACOPREFERENCE study.

dc.contributor.authorEscobar, Carlos
dc.contributor.authorBorrás, Xavier
dc.contributor.authorBover Freire, Ramón
dc.contributor.authorGonzález-Juanatey, Carlos
dc.contributor.authorMorillas, Miren
dc.contributor.authorMuñoz, Alfonso Valle
dc.contributor.authorGómez-Doblas, Juan José
dc.date.accessioned2023-02-09T09:35:19Z
dc.date.available2023-02-09T09:35:19Z
dc.date.issued2020-06-01
dc.description.abstractTo evaluate the level of agreement between cardiologists regarding the management of oral anticoagulation (OAC) in patients with non-valvular atrial fibrillation (NVAF) in Spain. A two-round Delphi study was performed using an online survey. In round 1, panel members rated their level of agreement with the questionnaire items on a 9-point Likert scale. Item selection was based on acceptance by ≥66.6% of panellists and the agreement of the scientific committee. In round 2, the same panellists evaluated those items that did not meet consensus in round 1. A total of 238 experts participated in round 1; of these, 217 completed the round 2 survey. In round 1, 111 items from 4 dimensions (Thromboembolic and bleeding risk evaluation for treatment decision-making: 18 items; Choice of OAC: 39 items; OAC in specific cardiology situations: 12 items; Patient participation and education: 42 items) were evaluated. Consensus was reached for 92 items (83%). Over 80% of the experts agreed with the use of DOACs as the initial anticoagulant treatment when OAC is indicated. Panellists recommended the use of DOACs in patients at high risk of thromboembolic complications (CHA2DS2-VASc ≥3) (83%), haemorrhages (HAS-BLED ≥3) (89%) and poor quality of anticoagulation control (SAMe-TT2R2 >2) (76%), patients who fail to achieve an optimal therapeutic range after 3 months on VKA treatment (93%), and those who are to undergo cardioversion (80%). Panellists agreed that the efficacy and safety profile of each DOAC (98%), the availability of a specific reversal agent (72%) and patient's preference (85%) should be considered when prescribing a DOAC. A total of 97 items were ultimately accepted after round 2. This Delphi panel study provides expert-based recommendations that may offer guidance on clinical decision-making for the management of OAC in NVAF. The importance of patient education and involvement has been highlighted.
dc.identifier.doi10.1371/journal.pone.0231565
dc.identifier.essn1932-6203
dc.identifier.pmcPMC7263623
dc.identifier.pmid32479502
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7263623/pdf
dc.identifier.unpaywallURLhttps://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0231565&type=printable
dc.identifier.urihttp://hdl.handle.net/10668/15666
dc.issue.number6
dc.journal.titlePloS one
dc.journal.titleabbreviationPLoS One
dc.language.isoen
dc.organizationHospital Universitario Virgen de la Victoria
dc.page.numbere0231565
dc.pubmedtypeJournal Article
dc.pubmedtypeResearch Support, Non-U.S. Gov't
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subject.meshAdministration, Oral
dc.subject.meshAdult
dc.subject.meshAnticoagulants
dc.subject.meshAtrial Fibrillation
dc.subject.meshDelphi Technique
dc.subject.meshFemale
dc.subject.meshHemorrhage
dc.subject.meshHumans
dc.subject.meshInternet
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshPatient Preference
dc.subject.meshPhysicians
dc.subject.meshSpain
dc.subject.meshSurveys and Questionnaires
dc.subject.meshThromboembolism
dc.titleA Delphi consensus on the management of oral anticoagulation in patients with non-valvular atrial fibrillation in Spain: ACOPREFERENCE study.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number15
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
PMC7263623.pdf
Size:
2.6 MB
Format:
Adobe Portable Document Format